GLUT1 sindrom deficijencije – prikaz bolesnika sa mutacijom u SLC2A1 genu
Sažetak
Uvod. GLUT1 sindrom deficijencije (GLUT1 DS, OMIM 606777) je metaboličko oboljenje mozga uzrokovano mutacijom u SLC2A1 genu (hromozom 1) koji kodira transporter glukoze tip 1 lokalizovan na krvno-moždanoj barijeri. “Klasični” fenotip kod dece uključuje ranu pojavu generalizovane farmakorezistentne epilepsije, usporen psihomotorni razvoj, poremećaje pokreta i stečenu mikrocefaliju. Međutim, blaži fenotipovi bez pojave epilepsije mogu se videti i u kasnijem uzrastu. Ketogena dijeta je terapija izbora. Prikaz bolesnika. U radu je prikazana devojčica, uzrasta četiri godine sa farmakorezistentnom generalizovanom epilepsijom, paroksizmalnim distonijama, ataksijom, hipotonijom, usporenim razvojem (poremećajima motorike, pažnje i govora) i mikrocefalijom. Genetsko testiranje je otkrilo novu tačkastu mutaciju u c.156T > A (p.Y52X) na egzonu 3 SLC2A1 gena. Kod bolesnice je primećeno poboljšanje u kliničkom nalazu na primenu ketogene dijete. Zaključak. GLUT1 DS je lečiva neurološka bolest, koja je verovatno nedovoljno prepoznata. Ketogena dijeta dovodi do povoljne kontrole napada kod dece, a doprinosi izvesnom poboljšanju u neurološkom nalazu.
Reference
Klepper J, Leiendecker B. GLUT1 deficiency syndrome-2007 update. Dev Med Child Neurol 2007; 49(9): 707–16.
De Vivo DC, Trifiletti RR, Jacobson RI, Ronen GM, Behmand RA, Harik SI. Defective glucose transport across the blood-brain barrier as a cause of persistent hypoglycorrhachia, sei-zures, and developmental delay. N Engl J Med 1991; 325(10): 703–9.
Pearson TS, Akman C, Hinton VJ, Kristin E, De Vivo DC. Phe-notypic spectrum of glucose transporter type 1 deficiency syn-drome (Glut1DS). Curr Neurol Neurosci Rep 2013; 13(4): 342.
Pong AW, Geary BR, Engelstad KM, Natarajan A, Yang H, De Vivo DC. Glucose transporter type I deficiency syndrome: epi-lepsy phenotypes and outcomes. Epilepsia 2012; 53(9): 1503–10.
Klepper J. GLUT1 deficiency syndrome in clinica practise. Epi-lepsy Res 2012; 100(3): 272–7.
Brockmann K. The expanding phenotype of GLUT1-deficiency syndrome. Brain Dev 2009; 31(7): 545-52.
Schneider SA, Paisan-Ruiz C, Garcia-Gorostiaga J, Quinn NP, We-ber YG, Lerche H et al. GLUT1 gene mutations cause sporadic paroxysmal exercise-induced dyskinesias. Mov Disord 2009; 24(11): 1684–8.
Post R, Collins A, Rotstein M, Engelstad K, De Vivo DC. The spectrum of movement disorders in Glut-1 deficiency. Mov Disord 2010; 25(3): 275–81.
Auberger G, Ratzlaft T, Lankes A, Nelles HW, Leube B, Binkofski F, et al. A gene for autosomal dominant paroxismal choreoathetosis/spasticity (CSE) maps to the vicinity of a po-tassium channel gene cluster on chromosome 1p, probably within 2cM between D1S443 and D1S197. Genomics 1996; 31(1): 90–4.
Weber YG, Kamm C, Suls A, Kempfle J, Kotschet K, Schule R, et al. Paroxysmal choreoathetosis/spasticity (DYT9) is caused by GLUT1 defect. Neurology 2011; 77(10): 959–64.
Larsen J, Johannesen KM, Ek J, Tang S, Marini C, Blichfeldt S, et al. The role of SLC2A1 mutations in myoclonic astatic epielp-sy and absence epilepsy, and the estimated frequency of GLUT1 deficiency syndrome. Epilepsia 2015; 56 (12): e203–8.
Akman CI, Provenzano F, Wang D, Engelstad K, Hinton V, Yu J, et al. Topography of brain glucose hypometabolism and epi-leptic network in glucose transporter 1 deficiency. Epilepsy Res 2015; 110: 206–15.
Wong HY, Chu TS, Lai JC, Fung KP, Fok TF, Fujii T, et al. So-dium valproate inhibits glucose transport and exacerbates Glut1-deficiency in vitro. J Cell Biochem 2005; 96(4): 775–85.
Baranano KW, Hartman AL. The ketogenic diet: uses in epilep-sy and other neurologic ilnesses. Curr Treat Options Neurol 2008; 10(6): 410–9.
Strafstrom CE, Rho JM. The ketogenic diet as a treatment par-adigm for diverse neurological disorders. Front Pharmacol 2012; 3: 59.
Gano LB, Patel M, Rho JM. Ketogenic diets, mitocondria, and neurological disease. J Lipid Res 2014; 55(11): 2211–28.
De Giorgis V, Teutonico F, Cereda C, Balottin U, Bianchi M, Giordano L, et al. Sporadic and familiar glut1ds Italian pa-tients: a wide clinical variability. Seizure 2015; 24: 28–32.
Leen WG, Klepper J, Verbeek MM, Leferink M, Hofste T, van Engelen BG, et al. Glucose transporter-1 deficiency síndrome: the expanding clinical and genetic spectrum of a treatable dis-order. Brain 2010; 133(Pt 3): 655–70.
De Giorgis V, Veggiotti P. GLUT1 deficiency síndrome 2013; current state of the art. Seizure 2013; 22(10): 803–11.
Melnikova AM, Korff CM. Clinical variability of GLUT1DS. Seizure Disord 2015; 29(2): 14.